Subsequently, an article in 2020 noted that there were significantly more PD-1+, CD8+, and CD45RO+ immune cells in Lynch syndrome EC than sporadic MLH1 hypermethylation tumors, and data from this article supported the possibility that Lynch syndrome might have a sustained antitumor immune response that is more sensitive to immune checkpoint blockade [21]. The gene discussed is MLH1; the disease is Lynch syndrome.